Analysts await Endologix, Inc. (NASDAQ:ELGX) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.28 EPS, down 50% or $0.14 from last year’s $-0.14 per share.

At the moment 10 analysts are watching Endologix, Inc. (NASDAQ:ELGX), 4 rate it “Buy”, 4 “Outperform”, 2 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 9 analysts have a mean sales target of 45.77 million. For the quarter ending Sep-16, 9 analysts have a mean sales target of 52.80 million whilst for the year ending Dec-16, 10 analysts have a mean target of 195.02 million.

In terms of earnings per share, 9 analysts have a -0.21 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 9 analysts have a -0.18 EPS mean target and for the quarter ending Sep-16 there are 9 estimates of -0.80 EPS.

The biggest institutional shareholders in Endologix, Inc. include Janus Capital Management LLC which owns 7 million shares in the company valued at $71.98 million. Cadian Capital Management, LLC is the second biggest holder with 6 million shares currently valued at 56.20 million whilst Tamarack Capital Management, LLC has 4 million shares valued at 44.30 million.

Total shares held by institutions as of the most recent company filings are 74,776,446 with a reported 12,353,642 bought and 12,269,358 sold. These holdings make up 91.56% of the company’s outstanding shares.

Currently insiders hold 3,398,354 shares in the business which makes up 4.16% of shares. The biggest holder currently is John McDermott who owns 667,506 shares (0.82% of those outstanding), whilst Edward Diethrich holds 553,775 (0.68% of shares outstanding) and Mr. Christopher G. Chavez holds 355,540 (0.44% of shares outstanding).

The stock increased 0.80% or $0.09 during the last trading session.